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ABSTRACT: Urinary expressed prostatic secretion or “EPS-urine” is proximal tissue fluid
that is collected after a digital rectal exam (DRE). EPS-urine is a rich source of prostate-
derived proteins that can be used for biomarker discovery for prostate cancer (PCa) and
other prostatic diseases. We previously conducted a comprehensive proteome analysis of
direct expressed prostatic secretions (EPS). In the current study, we defined the proteome of
EPS-urine employing Multidimensional Protein Identification Technology (MudPIT) and
providing a comprehensive catalogue of this body fluid for future biomarker studies. We
identified 1022 unique proteins in a heterogeneous cohort of 11 EPS-urines derived from
biopsy negative noncancer diagnoses with some benign prostatic diseases (BPH) and low-
grade PCa, representative of secreted prostate and immune system-derived proteins in a
urine background. We further applied MudPIT-based proteomics to generate and compare
the differential proteome from a subset of pooled urines (pre-DRE) and EPS-urines (post-
DRE) from noncancer and PCa patients. The direct proteomic comparison of these highly
controlled patient sample pools enabled us to define a list of prostate-enriched proteins detectable in EPS-urine and
distinguishable from a complex urine protein background. A combinatorial analysis of both proteomics data sets and systematic
integration with publicly available proteomics data of related body fluids, human tissue transcriptomic data, and immuno-
histochemistry images from the Human Protein Atlas database allowed us to demarcate a robust panel of 49 prostate-derived
proteins in EPS-urine. Finally, we validated the expression of seven of these proteins using Western blotting, supporting the
likelihood that they originate from the prostate. The definition of these prostatic proteins in EPS-urine samples provides a
reference for future investigations for prostatic-disease biomarker studies.
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■ INTRODUCTION
Recent advances in mass spectrometry (MS) instrumentation
and sample preparation methods have propelled proteomics
forward for the identification of biomarkers from body fluids
and tissue extracts.1 However, widespread clinical adaptation of
candidate protein biomarkers has been hampered, in part, by a
lack of suitable biological specimens. Serum or plasma samples,
for instance, offer accessibility and ease of collection but have a
high dynamic range (i.e., 10−12 orders of magnitude),2 thus
complicating the identification and quantification of low
abundance proteins and surpassing the capabilities of existing
separation and analysis techniques. Direct analysis of tumor
tissues potentially provides access to greater concentrations of
tumor-specific proteins but, tumor tissues are extremely hetero-
geneous and often represent a small proportion of the total
organ mass, resulting in unsatisfactory yields of tumor-specific
proteins.
Organ-proximal fluids, like breast ductal or prostatic
secretions, are alternative sources of biological material to
identify and quantify proteins that can mirror the physiological
state of a given tissue.3 Proximal fluids have been hypothesized
to be a rich source of biomarkers because of their high
concentration of shed and secreted proteins.4 In the current
study, we focus on the identification of prostate-derived
proteins from expressed prostatic secretions (EPS) obtained
via urine collection following digital rectal exam (DRE). These
EPS-urine samples are a potentially rich source of informative
Received: November 10, 2011
Published: February 16, 2012
Article
pubs.acs.org/jpr
© 2012 American Chemical Society 2386 dx.doi.org/10.1021/pr2011236 | J. Proteome Res. 2012, 11, 2386−2396
proteins that are secreted/released from the prostate into the
extracellular environment. Resolving disease-specific protein
expression signatures may be useful as diagnostic/prognostic
biomarkers, particularly if they are obtainable in a straight-
forward, noninvasive fashion. Thus, we have looked to EPS-
urine as a potentially informative resource of prostate-secreted
proteins and a clinically attractive biofluid that can be used to
routinely screen for prostatic disease biomarkers.
The exocrine compartment of the prostate is composed of
differentiated epithelial cells, that actively secrete proteins such
as prostate-specific antigen (PSA), prostatic acid phosphatase
(PAP), prostaglandins, vimentin and keratins, into the
glandular lumen.5 Upon application of DRE, these secretory
proteins, as well as immune response derived and cellular
proteins, are forced into the urethra and mixed with urine in the
urinary tract. These mixed fluids can then be collected in
voided urine (EPS-urine). Use of EPS-urine has some key
advantages over urine as a source of putative biomarkers of
prostatic conditions. Despite the complex urine protein
background of EPS-urine, there is increased potential for
detection of low abundance prostate-specific proteins in this
fluid. Due to the close proximity to the prostate, a higher
concentration of prostate-enriched proteins is achieved and
normally low abundance proteins are present at concentrations
that far exceed those found in serum. Such secreted/released
proteins may be involved in key pathways that lead to prostatic
disease formation and progression. Methodologies that can
selectively target prostate-enriched proteins would facilitate the
discovery of highly informative biomarkers and potential drug
targets. The value of EPS-urine is further enhanced by its
applicability to routine clinical diagnostics, due to its ease of
collection, enabling repeat and even longitudinal studies.6
The present study aimed to uncover the constituents of
EPS-urine by employing Multidimensional Protein Identifica-
tion Technology (MudPIT), to provide a valuable resource of
MS-detectable proteins. A cohort of EPS-urine samples
representative of the most common samples collected clinically,
from benign prostatic diseases and low-grade PCa, was analyzed
to provide a representative proteome catalogue of this fluid.
Similar to our recent investigation on direct-EPS, which is
obtained under anesthesia by prostate massage just prior to
prostatectomy,7 we have carefully analyzed this protein data-
base for functionally enriched categories. We also combined
this analysis using bioinformatics and compared our EPS-
proteome to several publicly available proteomics data sets of
related body fluids, including direct-EPS7 and urine.8 To
subselect for proteins likely secreted from the prostate in this
complex urine-protein background, we also performed a highly
controlled quantitative comparison of pooled samples collected
prior to DRE (urine) and post-DRE (EPS-urine) from men.
Importantly, these pre- and post- samples were collected from
the same patients, enabling direct quantitative intrapatient
comparisons to identify proteins that are up-regulated in the
post-DRE samples. The combination of these data and their
integration with publicly available proteomic,7,8 microarray data
from BioGPS portal (http://biogps.org/),9 and immunohis-
tochemistry images from the Human Protein Atlas (HPA;
http://www.proteinatlas.org/)10,11 allowed us to generate a
panel of 49 proteins likely secreted by the prostate and
detectable in EPS-urine. These proteins will be of relevance for
future investigations in larger EPS-urine cohorts as potential
prostate disease biomarkers as well as compelling candidates for
biological analyses.
■ MATERIALS AND METHODS
Materials
Ultrapure-grade urea, ammonium bicarbonate, ammonium acetate,
calcium chloride and Tris were from BioShop Canada, Inc.
(Burlington, ON, Canada). Ultrapure-grade iodoacetamide, DTT,
and formic acid were from Sigma-Aldrich. HPLC-grade solvents
(methanol, acetonitrile, and water) were obtained from Thermo
Fisher Scientific (San Jose, CA). Trifluoroacetic acid was from J.T.
Baker (Phillipsburg, NJ). Mass spectrometry-grade trypsin was from
Promega (Madison, WI). Solid-phase extraction C18 MacroSpin
Columns were from The Nest Group, Inc. (Southboro, MA).
EPS-Urine Collection and Concentration
All samples were collected from patients and utilized after
informed consent following Institutional Review Board-
approved protocols at Urology of Virginia and the Eastern
Virginia Medical School along with the Research Ethics Board
of the University Health Network. All personal information or
identifiers beyond diagnosis and lab results were not available
to the laboratory investigators. EPS-urine samples were
collected by performing a gentle massage of the prostate
gland during DRE prior to biopsy, as previously described.7 The
massage consisted of three strokes on each side of the median
sulcus of the prostate and the expressed fluid from the glandular
network of the prostate was subsequently voided in urine.
To generate sample pools from noncancer and cancer
patients, 10−20 mL of urine and EPS-urine were collected from
the same individual an hour before the DRE massage, herein
denoted as urine, and after DRE, herein denoted as EPS-urine.
Urine and EPS-urine from a group of 5 patients with PCa and 5
biopsy negative, noncancer individuals (Table 1), were pooled
together to generate a sample panel comprising 4 different
conditions: U_NC, urine noncancer; EPS-U_NC, EPS-urine
noncancer; U_Ca, urine cancer; EPS-U_Ca, EPS-urine cancer.
After collection, samples were stored on ice for no longer than
1 h. Each sample was aliquoted and stored at −80 °C until use.
Individual EPS-urines were obtained from an independent
cohort of 11 different patients: 5 with low-grade PCa and 6
with biopsy negative benign conditions (BPH) (Table 2).
Following collection, 9 mL of EPS-urine was centrifuged at
Table 1. Clinical Information for the Urine and EPS-Urine
Pooled Samples (NC and PCa) Analyzed by MudPITa
age serum PSA Gleason risk
NC 61 3.8 B
82 10.8 B
59 5.9 B
66 3.3 N
57 6.4 N
Mean ± SD 65 ± 10 6 ± 2.9
PCa 75 2.6 3 + 3 L
84 11.7 3 + 3 I
74 2.3 3 + 4 L
71 6.4 3 + 3 L
60 5.7 3 + 3 L
Mean ± SD 72.8 ± 8.6 5.7 ± 3.8
aUrine and EPS-urine sample pairs were collected from the same patient
and pooled together as described in Materials and Methods (serum PSA in
ng/mL). In the risk column, B denotes patients with BPH, N denotes
patients with no identifiable prostatic diseases, L denotes patients with low-
risk PCa, and I denotes patients with intermediate-risk PCa.
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14000× g to remove the cell pellet/sediment. The supernatant
was recovered and concentrated using an Amicon Ultra-15
Centrifugal Filter (3 kDa cutoff; Millipore, Billerica, MA)
according to the manufacturer’s instructions. Approximately
500 μL of each concentrated EPS-urine sample was recovered
from the filter device and stored at −80 °C until use.
Protein Digestion and Peptide Preparation
For MS analysis, all samples were first quantified using a
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific,
San Jose, CA) and volumes corresponding to 100 μg of total
protein for the pools and 150 μg of total protein for the
individual EPS-urines were resuspended in 50 μL of 8 M urea,
2 mM DTT, 50 mM Tris-HCl, pH 8.5, and incubated at 37 °C
with constant shaking for 30 min. Carbamidomethylation was
performed by incubating samples with 8 mM of iodoacetamide
for 30 min at 37 °C in the dark. Samples were then diluted to
approximately 1.5 M urea using 100 mM ammonium
bicarbonate, pH 8.5. Calcium chloride was added to a final
concentration of 2 mM and the protein mixture was digested
with trypsin (1:40 trypsin to protein ratio) at 37 °C overnight.
The digested peptide mixture was purified with C18 MacroSpin
columns and concentrated by vacuum centrifugation and
reconstituted to a volume of 40 μL with 0.1% formic acid.
Samples were stored at −80 °C until used for MudPIT analysis.
MudPIT Analyses
Individual EPS-urines (5 PCa and 6 BPH) were analyzed in
triplicate using a fully automated 9-cycle MudPIT procedure
as previously described.12,13 A quaternary HPLC pump was
interfaced with a linear ion-trap mass spectrometer (LTQ,
Thermo Fisher Scientific, San Jose, CA) equipped with a
nanoelectrospray source (Proxeon Biosystems, Odense,
Denmark). The pooled urine and EPS-urine samples were
analyzed in triplicate on a LTQ Orbitrap XL, using a modified
5-cycle MudPIT, as previously described.14
Protein Identification and Data Analysis
Raw data obtained from all MudPIT runs were converted to
m/z XML using ReAdW and searched by X!Tandem against a
locally installed version of the human UniProt complete human
proteome (www.uniprot.org) protein sequence database
(version 2010_06; number of entries 20295). A target/decoy
search was performed to experimentally estimate the number of
false-positive identifications (<1% estimated FDR) and an in-
house protein grouping algorithm was applied to satisfy the
principles of parsimony.15−17 The following parameters were
applied according to the instrument used:
LTQ analyses of individual EPS-urines. The search was
performed with a fragment ion mass tolerance of 0.4 Da and a
parent ion mass tolerance of 4 Da. Complete tryptic digest was
assumed. Carbamidomethylation of cysteine was specified as
fixed and oxidation of methionine as a variable modification.
Only proteins identified with two unique high-quality peptide
identifications per triplicate were considered, as previously
reported15−17 (11 decoy proteins identified; FDR ∼1%). Each
sample (n = 11) was examined by 3 technical replicates (33
total MudPIT analyses).
LTQ-Orbitrap XL analyses of pooled urines and EPS-
urines. The search was performed with a fragment ion mass
tolerance of 0.4 Da and a parent ion mass tolerance of ±10
ppm. Complete tryptic digest was assumed. Carbamidome-
thylation of cysteine was specified as fixed and oxidation of
methionine as variable modification. Only proteins identified
with two unique high quality peptide identifications per ana-
lyzed sample were considered, as previously reported14,18,19
(2 decoy proteins identified; FDR ∼0.5%). Each sample pool
was analyzed by ≥3 technical replicates (13 total MudPIT
analyses).
Protein relative abundance was calculated using the QSpec
algorithm.20 Proteins were considered to be up-regulated in the
pooled EPS-urine samples versus the urine samples if they
complied with the following parameters: false discovery rate
(FDR) <0.05 and fold change (FC) ≥ 2, based on the QSpec
algorithm.20
Gene Ontology Annotation and Data Comparison
Functional annotations (Gene Ontology terms, KEGG path-
ways, and Swiss Prot entries) were assigned using the Database
for Annotation, Visualization and Integrated Discovery
(DAVID, bioinformatics resources v6.7; http://david.abcc.
ncifcrf.gov/).21 Unique proteins detected in the EPS-urine
data set were compared to the UniProt database and the top
five significantly over-represented categories were reported
(p-value <0.001). Comparisons of the present EPS-urine data
set to urine8 and direct-EPS7 data sets was accomplished using
ProteinCenter (Proxeon Biosystems, Odense, Denmark).
Proteins were sequence-aligned against each other and only
proteins with at least 95% sequence identity were considered to
match (i.e., protein clusters).
Table 2. Clinical Information for the PCa (5 samples) and BPH (6 samples) Individual EPS-Urines Analyzed by MudPITa
age serum PSA Gleason stage treatment
PCa EPS-U1 59 9.2 3 + 3 T1c DVP
EPS-U2 66 1.9 3 + 3 T1c AS
EPS-U3 77 2.7 3 + 4 T2b Cryo
EPS-U4 73 5.9 3 + 3 T1c DVP
EPS-U5 53 6.0 3 + 3 T1c AS
Mean ± SD 65.6 ± 9.8 5.1 ± 2.9
BPH EPS-U6 76 4.5
EPS-U7 63 N/A
EPS-U8 57 3.2
EPS-U9 74 2.8
EPS-U10 54 4.3
EPS-U11 61 4.8
Mean ± SD 64.2 ± 8.9 3.9 ± 0.9
aSerum PSA values are from the time of initial diagnosis. The treatment column indicates the clinical course followed for each cancer patient
(DVP − Da Vinci prostatectomy; Cryo, cryoablation therapy; AS, active surveillance) (serum PSA in ng/mL).
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Prostate-Enriched Proteins Characterization
The BioGPS portal (http://biogps.org/)9 was used to map
identified proteins against available mRNA microarray data sets.
We selected 25 major organ systems among those available in
BioGPS and linked our proteins via gene accessions. The
expression level for each gene was based on averaged probe
intensities, and the significant enrichment in prostate tissue
(>2-fold change) was calculated as a log2 ratio compared to the
other selected tissues. The random sampling analysis was
carried out using the unpaired one-tailed Students̀ t test.
A p-value ≤0.05 was considered statistically significant. The
alphabetical roster of the selected organs is as follows: bone
marrow, colon, heart, hypothalamus, kidney, liver, lung, lymph
node, ovary, pancreas, placenta, prostate, salivary gland, skeletal
muscle, skin, small intestine, smooth muscle, spinal cord, testis,
thalamus, thymus, thyroid, uterus, whole blood, and whole
brain.
The UniProt database (http://www.uniprot.org/)22 was
used to assign subcellular localization to the 49 proteins
enriched in EPS-urine pooled samples. We manually re-
ported annotations and grouped the 49 proteins into three
main categories: secreted, membrane, and intracellular (which
includes cytoplasmic, nuclear, and lysosomal). Identified
proteins were also screened against the Human Protein Atlas
database (HPA; http://www.proteinatlas.org/)10,11 for avail-
ability of antibodies and to examine their prostate tissue ex-
pression patterns.
SDS-PAGE and Western blot analysis on urine and
EPS-urine pools
For Western blotting, 40 μg of total proteins were separated on
8 or 10% SDS-PAGE gels and blotted on PVDF membranes
(0.2 μm; Bio-Rad Laboratories, Hercules, CA). Membranes
were blocked with 5% milk in TBS-Tween (0.2%) for 1 h at
room temperature and subsequently incubated overnight at
4 °C with the following primary antibodies: anti-Lactoferrin
(1:1000 #ab10110; Abcam, Cambridge, U.K.), anti-CD10 (MME
1:1000 #ab951; Abcam, Cambridge, U.K.), anti-TIMP1 (1:2000
#RP1-TIMP1; Triple Point Biologics, Forest Grove, OR), anti-
CD13 (ANPEP 1:500 #ab7417; Abcam, Cambridge, U.K.), anti-
TGM4 (1:500 #sc55791; Santa Cruz Biotechnology, Santa
Cruz, CA), anti-14-3-3σ (1:250 #ab14123; Abcam, Cam-
bridge, U.K.), and anti−PARK7 (1:1000 #ab11251; Abcam,
Cambridge, U.K.). After three 10-min washes with TBS-
Tween (0.2%), membranes were incubated with antimouse/
antirabbit/antigoat IgG-HRP secondary antibody (Invitro-
gen, Carlsbad, CA) at a dilution of 1:25000 for 1 h at room
temperature, washed and visualized with the SuperSignal
West Pico chemiluminescent substrate (Thermo Fisher
Scientific, San Jose, CA).
■ RESULTS AND DISCUSSION
Proteome Profiling of EPS-Urine
One goal of the current study was to provide a high-quality,
well-annotated resource of proteins present in EPS-urine. This
could improve our understanding of general prostate biology
in the aging male and guide the discovery of novel PCa
biomarkers. While commercial genetic assays have been
developed using EPS-urines as a source of prostate-derived
genetic material,23−25 an in-depth proteomic analysis of
this fluid has not been reported. In contrast to direct-EPS,7
which is likely to contain prostate-secreted proteins at a higher
concentration, EPS-urine is highly diluted by a dynamic and
variable urine background. Nevertheless, EPS-urine samples are
clinically more relevant since they can be obtained by routine
DRE examination, and can be collected repeatedly for
longitudinal sample collection relevant to active surveillance
monitoring of men with PCa.
There were two interconnecting aims to our current study
(Figure 1). The first aim was to provide the first in-depth
proteome catalogue of this clinically useful proximal tissue fluid
(Figure 1, Left panels), in order to standardize the proteome of
EPS-urine based on clinical collection procedures that can be
performed in a routine clinical setting. In particular, individual
EPS-urine samples from men diagnosed with low-grade PCa
(n = 5; Gleason total 6−7) and biopsy negative benign
conditions (n = 6, BPH) were selected for MudPIT-based
proteomic analysis (Table 2). The proteomic characterization
of the EPS-urine was performed on this heterogeneous group
of 11 samples as a representation of the different types of
patient origin, reflective of the most common benign and
prostate cancer conditions presenting in urology clinics. Each
sample of 150 μg total protein was directly digested in-solution
and analyzed in triplicate by a 9-step MudPIT on a LTQ-Ion
Trap mass spectrometer, as previously described.12,15 A total of
1022 unique proteins were identified in the EPS-urines
(Supplemental Table 1, Supporting Information) by at least
two unique peptides (Figure 1, Left panels of flowchart),
ranging from 178 to 667 unique proteins determined per
individual MudPIT run (Figure 2A). Although the same
amount of total protein was digested and each sample was
analyzed in triplicate with a relatively low overall standard
deviation (average standard deviation of 27), there was still a
large variation in total proteins detected for each sample. This
high variability is reflective of the biological intersample
variations among human specimens, which complicates data
profiling analyses, as well as of the dynamic metabolic changes
within each individual that are manifested in urine protein
content,26 and highlights some of the general problems of
proteomic analyses of proximal body fluids.27 These results
could also reflect variation in sample collection, as the DRE
procedure required to “express” the prostatic fluids will be
different for each individual.6 Other known limitations are
related to the DRE-collection procedure and can be attributed
to the physician (e.g., size of hand, ability to reach to the
prostate, etc.) or to some patient physical parameters (e.g.,
orientation on table during examination, overweight status,
etc.). Therefore, standard collection protocols as well as
internal standards are required to ensure proper collection
and to circumvent the introduction of sample variability
resulting from the collection procedure.6
To obtain a systematic overview of the functional categories
of proteins expressed in EPS-urine, we performed Gene
Ontology (GO)28 and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways analyses29 on the 1022 identified
proteins (Figure 3). We limited the comparison to several
representative GO terms in order to obtain a high-level
functional overview. In the biological processes category, a large
proportion of identified proteins had functional roles involved
in proteolytic activity, cellular adhesion and motion, and
immune responses (Figure 3A). In the cellular component
category (Figure 3B), GO terms with an annotation to the
extracellular region were overrepresented; this was further
supported by the evidence that ∼50% of the detected proteins
were classified in the Swiss-Prot database as proteins with signal
peptide sequences, and more than 30% were classified as
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secreted proteins (Figure 3D). Notably, 12% of the EPS-urine
proteins contained the annotation of vesicle localization by GO
(Figure 3B); this could explain why the lysosomal pathway is
the most highly over-represented among the KEGG pathways
in our EPS-urine data set (Figure 3E).
In the molecular function category, a large proportion of
detected proteins had calcium ion binding activity and were
involved in the regulation of peptidase activity (Figure 3C).
On the basis of the global GO-term analyses, EPS-urine pro-
teins belong to a large variety of functional categories and, as
expected from a secreted fluid fraction, a large number of
these proteins are extracellular and contain a signal peptide
sequence.
To further characterize the EPS-urine proteome in the
context of other prostate-related fluids, the current data set was
integrated with normal human urine8 and direct-EPS,7 which
showed that 455 proteins are shared between these fluids by
proteomics analyses (Figure 3F). Present among these shared
proteins were several previously proposed PCa biomarkers (i.e.,
PSA, PAP, MSMB, PSMA, TMPRSS2), strengthening the
rationale of using in vivo-obtainable fluids to study the prostate
and PCa biology. On the other hand, these candidates were
detected in all three fluids, which demonstrates the dilemma in
detecting prostate-enriched proteins in a complex protein
background of general urine proteins.
Focusing on prostatic secretions, we found that 181 proteins
were shared between EPS-urine and direct-EPS (Figure 3F),
suggesting that these proteins are specifically enriched in
Figure 1. Study workflow. Proteomic analysis of EPS-urine and urine samples. The EPS-urine proteome was defined by MudPIT analyses of 11
individual heterogeneous samples (PCa and BPH) of EPS-urine. A similar analysis was performed on pooled urine and EPS-urine samples (PCa and
NC). The comparison of the two data sets using bioinformatics data mining lead to the identification of some putative prostate-enriched candidates
within the complex EPS-urine proteome.
Figure 2. Characterization of the EPS-urine proteome. Number of
unique proteins detected per MudPIT run respectively in the (A)
individual EPS-urine samples and in the (B) pooled urine and EPS-
urines. The black dots in A (from EPS-U1 to EPS-U5) represent the
EPS-urines from individual PCa patients and the white dots (from
EPS-U6 to EPS-U11) represent the EPS-urines from individual BPH
patients. Every sample was analyzed in triplicate. (EPS-U, EPS-urine;
U, urine; Ca, prostate cancer; NC, noncancer).
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prostatic secretions and absent or at a very low concentration in
urine. This could represent a useful protein data set for
selecting new prostate-specific biomarkers with diagnostic and
prognostic capacities for prostatic diseases. Interestingly, 113
proteins were unique to EPS-urine (absent from direct-EPS and
urine). This could be explained by different MS conditions used
between our group and the study by Adachi et al.,8 as well the
phenomenon of random sampling30 and biological variability,
since neither study was likely successful in detecting the entire
body fluid proteome and a different, nonoverlapping number of
false negatives are likely present.
The present study provides a detailed description of EPS-
urine and extensively expands the knowledge of EPS-urine
proteome. Our data set of 1022 proteins (Supplemental Table
1, Supporting Information) can be used to implement
diagnostic test platforms and improve current screening
procedures for prostatic diseases.
Identification of Prostate-Enriched Proteins
A second aim of this current study was to provide the first
direct comparison of urine samples pre- and post-DRE using
pooled samples from both normal and PCa patients (Figure 1,
right). These valuable samples enabled us to identify proteins
likely released by the prostate as a result of the DRE. We
identified prostate-enriched proteins derived from EPS-urines
in a complex protein background of general urine proteins. For
this purpose, five patients with PCa and five noncancer individuals
were screened once prior to DRE and once after DRE, in order to
obtain internally controlled urines and EPS-urines, respectively.
Each sample pool was analyzed by a 5-step MudPIT on a LTQ-
Orbitrap, leading to the identification of 444 unique proteins
(Supplemental Table 1, Supporting Information) (Figure 1, right),
with a range of 141 to 258 unique proteins determined per
individual MudPIT run (Figure 2B).
In order to highlight signatures of proteins enriched in the
EPS-urine, we next performed a semiquantitative comparative
analysis of the EPS-urine and urine data, based on the QSpec
algorithm.20 Proteins were considered to be prostate-enriched if
they had a ≥2-fold change in spectral abundance factors20,30
with a FDR ≤0.05 by QSpec analysis. Applying these criteria to
the entire list of 444 proteins, a panel of 49 significantly
enriched proteins was generated (Supplemental Table 2,
Supporting Information). Interestingly, direct comparison of
Figure 3. Functional enrichment of proteins detected in EPS-urine and comparison of the EPS-urine proteome to other related body fluids. The list
of the 1022 unique proteins identified in the EPS-urine samples was compared to the human UniProt Database. The reported graphs show
significantly over-represented (p < 0.001) Gene Ontology (GO) terms (A−C), Swiss-Prot entries (D), and KEGG pathways (E) in the EPS-urine
data set (several representative annotation terms are shown). (F) Current EPS-urine data set was compared to previously published urine8 and
direct-EPS7 proteomic data sets. Proteins are clustered in homogeneous groups based on 95% similarity (i.e., cluster anchors).
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both proteomic data sets (1022 versus 444) showed an overlap
of 406 proteins that included the 49 protein signature of
“prostate-enriched proteins” (Figure 4).
The prostate tissue selectivity of the 49 identified protein
signature was also evaluated at the transcriptome level (Figure
5A). The 49 proteins were mapped in the BioGPS database,
and the gene expression profiles for normal human prostate
tissue were compared to 24 other major normal human tissues,
under the assumption that transcript levels measured by
microarrays can be correlated with protein abundance.12
Although it is well-known that expression levels of both
biomolecules are not always concordant,15,31,32 our own
experience suggests reasonable correlation if the data is locked
on the protein level (i.e., using only transcripts with available
proteins evidence).15 This type of comparison can provide
additional evidence for prostate-enriched expression levels,
similar to our previous investigations.7 Genes with prostate
expression levels 2-fold above the median across all 25 tissues
were considered to be prostate-enriched. The distribution of
this analysis is shown in Figure 5A and represents the ex-
pression level of each gene coding for the 49 selected proteins
in the prostate tissue. Among the 49 selected gene products we
identified several well-known prostate biomarkers, such as PSA
(KLK3), MSMB and ACPP (highlighted in green), supporting
our hypothesis that direct comparison of urine and EPS-urine
by semiquantitative proteomics results in the identification of
prostate-enriched proteins suitable for further investigation in
biomarker studies.
According to this analysis, 32 of the 49 informative genes are
enriched in the prostatic tissue. The genes indicated with red
bars in the graph correspond to the seven proteins for which we
obtained antibodies and were able to verify the MS-based
proteomics data. Only 5 of 7 of these prostate-enriched genes
have high expression levels in prostate. Incidentally, we decided
to include all the seven candidates in our following analyses,
mainly based on manual annotations and comparisons with
other in-house proteomic data sets (unpublished data), that we
believe may be more accurate to capture relevant information.
We next examined a random sampling of our data set to
address the question of chance selection in arriving at our 49-
protein list. We randomly selected (10000 times) proteins from
the entire list of 1022 proteins we detected in EPS-urine, to
evaluate if a random selection from a larger data set of EPS-
urine proteins gave us the same probability to select prostate-
enriched proteins. The boxplot shown in Figure 5B reports the
comparison between the two data sets. As expected, our short-
list of 49 selected proteins is enriched in prostate-specific
proteins when compared with a random assortment of 10000
selections from the same EPS-urine database. The median
values of the two distributions tend to be lower in the random
sampling analysis (median =0.6) compared to our selection
(median =2.2) with a highly significant P-value of 0.000114.
Characterization of Prostate-Enriched Proteins
To better characterize our list of prostate-enriched proteins we
annotated information available at the HPA10,11 and UniProt
databases.22 As shown in Figure 6A, 38 proteins (78%) of all 49
have at least one antibody ID (Supplemental Table 2,
Supporting Information) available at the HPA,10,11 which was
validated and used to generate tissue expression profiles. In
Figure 6A, we further indicated the protein expression patterns
based on the immunohistochemistry images available in the
database. The evaluation of these images, based on staining
intensity and protein distribution in the human normal prostate
tissue, suggested that 45% of the proteins positivity was found
in the glandular epithelium, only 13% in the stromal cells and
29% showed equal staining between the two compartments.
As reported, most of the selected proteins are secreted and
hence preferentially expressed in glandular epithelial cells
(poorly expressed or absent by stromal cells) along with the
physiological function of the prostate gland.
Together protein tissue distribution and cellular localization
are parameters that can provide important insight into the
function of a protein. As expected, the respective subcellular
patterns reported from UniProt database22 were correlated
(Figure 6B) with other additional information collected from
other available resources (i.e., ProteinCenter, signal peptide
annotations) (Supplemental Table 2, Supporting Information).
The majority (33%) of the proteins in the analyzed EPS-urine
samples were secreted (without overlap with the other categories)
(Figure 6B). This localization is consistent with the biological
expectation that urine contains, by definition, many extracellular
proteins. Another significant percentage of proteins (22.5%) were
localized to the membrane compartment.
Interestingly, although the EPS-urine is not enriched in
intracellular proteins (18.4%), almost half (44%) of this
category consist of lysosomal proteins. This probably points
out that exosome formation is the dominant excretion pathway
in urine and reflects the biological and physiological role of
these proximal fluids, through the presence of specific transport
pathways for lysosomal proteins.
Generation of Candidate Short-list
Our analyses suggested an enrichment of prostate-specific
proteins in the EPS-urines compared to the urine samples.
Figure 4. Comparison between the two proteomics data sets of the
current study. The Venn diagram shows a comparison between the
EPS-urine data set (1022 proteins) and the data set containing
proteins identified in both pooled urine and EPS-urine samples (444
proteins). The overlapping area of 406 proteins includes a short-list of
proteins enriched in the EPS-urine samples compared to the urine
samples (termed prostate-enriched proteins).
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In particular, the list of 49 proteins (Supplemental Table 2,
Supporting Information) encompasses a number of prostate-
specific markers that are currently used or have been previously
considered as potential candidates for PCa screening; among
these are PRSP or MSMB (Microseminoprotein-β),33 KLK3 or
PSA (Prostate-specific antigen),34,35 ACPP or PAP (Prostatic
acid phosphatase) reported in 1938 as the first serum
biomarker for PCa,36,37 TMPRSS2 (Transmembrane protease
serine 2),38 FOLH1 or PSMA (Prostate-specific membrane
antigen).39
Each of the 49 differentially expressed proteins were
manually inspected for selection as part of a small verification
set aimed at validating the findings from our proteomic
investigations. Selection was largely based on antibody
availability; but other unbiased considerations were tissue
expression patterns of candidates across PCa and normal
prostate tissues available through the Human Protein Atlas,10,11
tissue specificity based on mRNA microarray data (see above),
subcellular localization by Gene Ontology analysis, and in-
house proteomic data sets generated from urines and prostatic
fluids from various conditions (unpublished data). This led to a
short-list of 7 proteins that were assayed in the verification
stage.
Verification of Proteomic Data
To verify our proteomic data, Western blot analyses were
carried out for each of the 7 candidates in pooled EPS-urines
and urines from PCa and noncancer patients. The panel in
Figure 7A shows that each of our short-listed candidates is
more abundant in EPS-urine samples compared to the
matching urines, supporting results from our MudPIT analyses.
In particular, by comparing noncancer and PCa EPS-urines, we
Figure 5. Data mining to identify prostate-enriched proteins. (A) Comparison of the 49 prostate-enriched proteins to published human tissue
transcriptomic data from the BioGPS gene portal.9 On the X-axis gene names are shown and the Y-axis represents a scale indicating the gene expression
level in prostate as compared to 24 additional human tissues. The Y-values were obtained as log2 [fold change] ratio of prostate gene expression level versus
the median value calculated for 25 major organs (listed in Materials and Methods). Green bars highlight protein biomarkers already suggested as candidates
for PCa prognosis and diagnosis (used as internal positive controls). Red bars highlight the 7 proteins that have been validated in this study. Red line
demarcates the 2-fold increased expression level in normal prostate as compared to all other tissues. (B) Box plot shows prostate-enriched proteins in the 49
selected data set versus a random sampling analysis on EPS-urine current data set. The Y-axis has the same log2 scale reported in A, rectangles are bounded
by the lower and upper quartiles, the solid lines in the rectangles are the medians, the box whiskers extend to the minimum to the maximum data point of
the rectangle, and the circles represent outliers beyond this range. *** P-value < 0.001.
Figure 6. Additional annotations for prostate-enriched proteins. (A)
Availability of antibodies reported in the Human Protein Atlas
database, for the 49 selected proteins. The IHC images were manually
screened and protein distribution was annotated (glandular cells or
stroma). (B) Subcellular location of the 49 prostate-enriched
according to UniProt database (red, protein number).
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observed the down-regulation of TGM4, LTF, ANPEP, MME and
TIMP1, and up-regulation of PARK7 and 14-3-3σ (Figure 7A),
which correlated with our proteomic data analyses. These
preliminary results also follow a similar trend when looking at
immunohistochemical staining patterns in normal and neoplastic
prostatic tissues via Human Protein Atlas,10,11 but will require
further verification in large unrelated EPS-urine cohorts in the
future (Figure 7B).
To the best of our knowledge, the current study represents
the most comprehensive catalogue of the EPS-urine proteome,
and can serve as a resource of MS-detectable prostate-enriched
proteins in this proximal tissue fluid. The proteomic character-
ization of EPS-urine provides a valuable reference for future
studies as an in-depth view of potential signatures that may be
indicative of various prostatic conditions. A better under-
standing of this fluid may facilitate the development of highly
sensitive and rapid assays that are specific for a given prostatic
disease. Evidently, greater numbers of samples need to be
assayed to better define the differences between cancer and
noncancerous states, and laying the groundwork for the
discovery of putative PCa biomarkers. In this proof-of-concept
study, we have demonstrated the value of EPS-urine as a rich
source of MS-detectable prostate-enriched proteins that can be
used for future investigation in biomarker discovery studies.
■ SUMMARY
We employed EPS-urine as a relevant and easily collectable
organ-proximal fluid for the identification of prostate-secreted
proteins in vivo. Our proteomic analyses provide a global
characterization of the most prevalent components of EPS-
urine and contribute to a better understanding of this
fluid. From this wide protein background, we narrowed our
Figure 7. Validation of MS data for seven selected proteins. (A) Western blot analyses of the seven candidate proteins confirmed the proteomic data
(based on spectral counts) showing an enrichment of each selected protein in the EPS-urine compared to the urine samples. (B)
Immunohistochemistry images obtained from Human Protein Atlas database showing the differential expression in normal and cancerous prostate
glandular tissue of the seven selected proteins. The same trend was obtained by MS and Western blot analysis. (U_NC, urine noncancer; EPS-
U_NC, EPS-urine noncancer; U_Ca, urine cancer; EPS-U_Ca, EPS-urine cancer).
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investigation to select proteins likely secreted from the prostate,
derived from the EPS component. We delineate a prostate-
enriched protein signature in the complex urine-protein
background, performing a highly controlled quantitative
comparison of urine and EPS-urine data sets. Our final data
demonstrate the value of EPS-urine as a rich source for protein
biomarker discovery and provide an in-depth view of proteins
that may be used as potential prostate-specific biomarkers for
prostatic diseases. The identification of new biomarkers in
proximal fluids may facilitate the development of highly
sensitive and rapid assays, specific for a given prostatic disease,
including PCa screening.
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